









Markets
/
Stocks
/
nasdaq-mens
/

Jyong Biotech Ltd

MENS

View Detailed Chart

13.800USD

+2.020+17.15%

Close 07/25, 16:00（ET）Quotes delayed by 15 min

1.05BMarket Cap

--P/E TTM



Jyong Biotech Ltd

13.800

+2.020+17.15%

Overview Company Financials

Financials

Intraday

30m

Today

+17.15%

5 Days

+30.81%

1 Month

+66.47%

6 Months

0.00%

Year to Date

0.00%

1 Year

0.00%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(0)

Neutral(0)

Buy(3)

Indicators

Sell(0)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

RSI(14)

STOCH(KDJ)(9,3,3)

ATR(14)

CCI(14)

Williams %R

TRIX(12,20)

StochRSI(14)

Moving Average

Sell(0)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

MA10

MA20

MA50

MA100

MA200

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.

Ticker SymbolMENS

CompanyJyong Biotech Ltd

CEO

Websitehttps://jyongbio.com/